These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37521493)

  • 1. Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss.
    Ma L; Zhang L; Liao Z; Xiu C; Luo X; Luo N; Zhang L; He G; Chen J
    J Orthop Translat; 2023 Sep; 42():1-14. PubMed ID: 37521493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade.
    Zhang L; Yang Y; Liao Z; Liu Q; Lei X; Li M; Saijilafu ; Zhang Z; Hong D; Zhu M; Li B; Yang H; Chen J
    Theranostics; 2020; 10(15):6638-6660. PubMed ID: 32550895
    [No Abstract]   [Full Text] [Related]  

  • 3. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation.
    Guo W; Li H; Lou Y; Zhang Y; Wang J; Qian M; Wei H; Xiao J; Xu Y
    J Orthop Translat; 2021 May; 28():148-158. PubMed ID: 33981577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asiatic Acid Attenuates Osteoporotic Bone Loss in Ovariectomized Mice Through Inhibiting NF-kappaB/MAPK/ Protein Kinase B Signaling Pathway.
    Dong M; Zeng J; Yang C; Qiu Y; Wang X
    Front Pharmacol; 2022; 13():829741. PubMed ID: 35211021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclareol inhibits RANKL-induced osteoclastogenesis and promotes osteoblastogenesis through promoting CCN1 expression via repressing the MAPK pathway.
    Li X; Wang Y; Li L; Zhou S; Zhao F
    Cell Biol Toxicol; 2021 Dec; 37(6):849-871. PubMed ID: 33423118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway.
    Qiu Z; Li L; Huang Y; Shi K; Zhang L; Huang C; Liang J; Zeng Q; Wang J; He X; Qin L; Wang X
    J Orthop Translat; 2022 Mar; 33():55-69. PubMed ID: 35228997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of a prominent dihydroxyflavanone pinocembrin for osteolytic bone disease:
    Hong G; Li S; Zheng G; Zheng X; Zhan Q; Zhou L; Wei Q; He W; Chen Z
    J Orthop Translat; 2024 Mar; 45():197-210. PubMed ID: 38685969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
    Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
    Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss.
    Han SY; Kim YK
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.
    Tran PT; Dang NH; Kim O; Van Cuong P; Dat NT; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Jun; 59():152908. PubMed ID: 30981187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
    Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
    J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosavin suppresses osteoclastogenesis
    Zhang W; Zhang W; Huo L; Chai Y; Liu Z; Ren Z; Yu C
    Ann Transl Med; 2021 Mar; 9(5):383. PubMed ID: 33842604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anethole inhibits RANKL-induced osteoclastogenesis by downregulating ERK/AKT signaling and prevents ovariectomy-induced bone loss in vivo.
    Qu H; Zhang Y; He R; Lin N; Wang C
    Int Immunopharmacol; 2021 Nov; 100():108113. PubMed ID: 34530203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.